肝病治療市場規模、佔有率和成長分析：按疾病、藥物類別、給藥途徑、分銷管道和地區分類－2026-2033年產業預測

2024 年全球肝病治療市場價值為 236.4 億美元，預計到 2025 年將成長至 255.5 億美元，到 2033 年將成長至 476.5 億美元，在預測期（2026-2033 年）內複合年成長率為 8.1%。

由於慢性肝病（包括非酒精性脂肪肝和病毒性肝炎）的盛行率不斷上升，全球肝病治療市場正經歷顯著成長。該市場涵蓋旨在預防、治療和監測肝病的藥物、生技藥品、再生醫學和診斷技術。隨著疾病發生率的上升，診斷和治療方法也在不斷進步，從而形成良性循環：早期發現刺激了對有效治療方法的需求，進而推動了投資。此外，肥胖和糖尿病的增加也推動了有針對性的篩檢計畫。諸如非侵入性生物標記和人工智慧解決方案等創新技術，最終透過改善患者管理、促進標靶治療、最佳化化合物研發和簡化臨床試驗，正在改變肝病的治療方式。

全球肝病治療市場按疾病、藥物類別、給藥途徑、分銷管道和地區進行細分。依疾病分類，市場分為非酒精性脂肪性肝炎（NASH/MASH）、病毒性肝炎、肝硬化、肝癌（肝細胞癌）、自體免疫肝病和其他疾病。依藥物類別分類，市場分為抗病毒藥物、標靶治療/免疫療法、皮質類固醇/免疫抑制劑、抗纖維化/代謝調節劑和化療。依給藥途徑分類，市場分為口服製劑和注射/靜脈輸注。按分銷管道分類，市場分為醫院藥房、零售藥房和線上藥房。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球肝病治療市場成長要素

肝臟疾病的日益普遍推動了對肝臟診斷和治療的需求，促使相關領域的投資大幅增加，治療產品線也隨之擴展。隨著越來越多的人受到這些疾病的影響，臨床上需要持續投入資源，以支持研發、生產和商業化活動。為此，醫療機構和保險公司正在整合篩檢和治療方案，加速創新產品在市場上的應用。製藥公司也正在加速開發新的治療方案，以填補現有的治療空白。同時，產學合作正在促進科學發現向實用治療方法的轉化，進一步推動市場成長並保持持續的商業性活力。

全球肝病治療市場的限制因素

肝病治療藥物研發成本的飆升給市場帶來了巨大挑戰，限制了能夠進入各個階段（包括廣泛的研究和臨床試驗）的候選藥物數量。這些試驗需要大量資源，加上特殊的生產要求，增加了申辦者的財務風險，常常阻礙中小企業專案的進展。因此，預算限制迫使各機構優先考慮後期項目或進行選擇性合作，對治療產品線的多樣性產生了負面影響。這種情況導致創新進程失衡，限制了新療法的可及性，並最終阻礙了整體市場發展和相關人員的參與。

全球肝病治療市場趨勢

全球肝病治療市場正經歷著向精準醫療的顯著轉變，其特點是根據每位患者的個別生物學特徵量身定做個人化治療策略。這一趨勢強調基於生物標記的方法、靶向抗病毒藥物的研發以及免疫調節劑的應用，從而帶來更個人化的醫療體驗。隨著患者分層在治療方案製定中變得至關重要，診斷和治療藥物研發人員之間的合作日益密切，推動著以價值為導向的適應性臨床策略的發展。這種對生物學證據的關注旨在滿足患者的多樣化需求，並最終提高真實臨床環境中的治療效果，提供長期的疾病管理解決方案。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球肝病治療市場規模：依疾病分類

• 非酒精性脂肪性肝炎（NASH/MASH）
• 病毒性肝炎
  • B型肝炎
  • C型肝炎
• 肝硬化
• 肝癌（肝細胞癌）
• 自體免疫肝病
• 其他

全球肝病治療市場規模：依藥物類別分類

• 抗病毒藥物
• 標靶治療和免疫治療藥物
• 皮質類固醇和免疫抑制劑
• 纖維化抑制劑和代謝調節劑
• 化療

全球肝病治療市場規模：依給藥途徑分類

• 口服製劑
• 注射藥物/靜脈輸液

全球肝病治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球肝病治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Gilead Sciences
• AbbVie
• Bristol-Myers Squibb
• Merck & Co
• Johnson & Johnson
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Sanofi
• Pfizer
• Novartis
• AstraZeneca
• Bayer AG
• Takeda Pharmaceutical
• Eisai Co
• Shionogi
• Intercept Pharmaceuticals
• Madrigal Pharmaceuticals
• Akero Therapeutics
• 89bio
• Viking Therapeutics

結論與建議

Global Liver Diseases Therapeutics Market size was valued at USD 23.64 Billion in 2024 and is poised to grow from USD 25.55 Billion in 2025 to USD 47.65 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global liver disease therapeutics market is experiencing significant growth due to the increasing prevalence of chronic liver conditions such as nonalcoholic fatty liver disease and viral hepatitis. This market encompasses pharmaceuticals, biologics, regenerative therapies, and diagnostics aimed at preventing, treating, and monitoring liver disorders. The rise in disease incidence is paralleled by advancements in diagnostics and treatments, creating a feedback loop where early detection spurs demand for effective therapies, subsequently fueling investment. Additionally, the rise of obesity and diabetes is driving focused screening programs. Innovations such as noninvasive biomarkers and AI-driven solutions are enhancing patient management and enabling the shift towards targeted therapies, optimizing compound development and streamlining clinical trials, ultimately reshaping the therapeutic landscape for liver diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Diseases Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Diseases Therapeutics Market Segments Analysis

The global liver diseases therapeutics market is segmented by disease condition, drug class, route of administration, distribution channel and region. Based on disease condition, the market is segmented into Non-Alcoholic Steatohepatitis (NASH / MASH), Hepatitis Viral Infections, Liver Cirrhosis, Liver Cancer (Hepatocellular Carcinoma), Autoimmune Liver Diseases and Others. Based on drug class, the market is segmented into Antiviral Drugs, Targeted & Immunotherapy Agents, Corticosteroids & Immunosuppressants, Fibrosis Inhibitors & Metabolic Regulators and Chemotherapy. Based on route of administration, the market is segmented into Oral Formulations and Injectable / Intravenous Infusions. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Diseases Therapeutics Market

The growing prevalence of liver disorders has led to a heightened demand for liver diagnostics and therapeutics, prompting significant investments and expansion of treatment pipelines. As more individuals are affected by these conditions, there is an ongoing clinical necessity that supports resource allocation across research, manufacturing, and commercialization activities. In response, healthcare providers and payers are integrating screening and treatment protocols, which fosters the adoption of innovative products in the market. Pharmaceutical enterprises are accelerating the development of new therapeutic options to address existing gaps, while collaborations between academia and industry are aiding the translation of scientific discoveries into viable treatments, further propelling market growth and sustained commercial interest.

Restraints in the Global Liver Diseases Therapeutics Market

The escalating costs associated with the development of liver disease therapies pose significant challenges for the market, limiting the number of candidates able to advance through the extensive phases of research and clinical trials. The resource-heavy nature of these trials, combined with specialized manufacturing demands, heightens financial risks for sponsors, often discouraging smaller companies from pursuing their programs. Consequently, budget constraints lead organizations to prioritize later-stage projects or engage in selective partnerships, which adversely affects the diversity of the therapeutic pipeline. This scenario creates an imbalanced rate of innovation and restricts access to new treatments, ultimately hindering the overall progression of the market and stakeholder involvement.

Market Trends of the Global Liver Diseases Therapeutics Market

The Global Liver Diseases Therapeutics market is witnessing a significant shift towards precision therapies, characterized by the personalization of treatment strategies that align with individual patient biology. This trend emphasizes biomarker-driven approaches, the development of targeted antivirals, and the use of immune modulators, fostering a more tailored healthcare experience. As patient stratification becomes integral to treatment plans, the market is seeing increased collaboration between diagnostics and therapeutic developers, promoting adaptive clinical strategies that emphasize value-based outcomes. This focus on biologic rationale caters to diverse patient needs, ultimately aiming to enhance real-world treatment efficacy and long-term disease management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Liver Diseases Therapeutics Market Size by Disease Condition & CAGR (2026-2033)

• Market Overview
• Non-Alcoholic Steatohepatitis (NASH / MASH)
• Hepatitis Viral Infections
  • Hepatitis B
  • Hepatitis C
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)
• Autoimmune Liver Diseases
• Others

Global Liver Diseases Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antiviral Drugs
• Targeted & Immunotherapy Agents
• Corticosteroids & Immunosuppressants
• Fibrosis Inhibitors & Metabolic Regulators
• Chemotherapy

Global Liver Diseases Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral Formulations
• Injectable / Intravenous Infusions

Global Liver Diseases Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Liver Diseases Therapeutics Market Size & CAGR (2026-2033)

• North America (Disease Condition, Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Disease Condition, Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Condition, Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Condition, Drug Class, Route of Administration, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Condition, Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intercept Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Madrigal Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akero Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 89bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations